BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, May 4, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 28, 2017
View Archived Issues
Roche details development of the first V1aR antagonist for social communication deficits in autism
Read More
MeiraGTx updates progress of AAV-mediated ocular gene therapy programs
Read More
Novel soluble S1P carrier shows efficacy in preclinical models of hypertension and ischemic injury
Read More
Long-term cMD1 gene therapy shows efficacy in a canine model of Duchenne muscular dystrophy
Read More
FDA approves Kedrab for post-exposure prophylaxis of rabies infection
Read More
Actemra approved in Japan for additional indications of Takayasu arteritis and giant cell arteritis
Read More
Mavenclad granted European approval for the treatment of highly active relapsing MS
Read More
Vimpat approved in Japan as monotherapy for partial onset seizures in patients with epilepsy
Read More
Initial clinical experience reported for AZD-5718 in healthy subjects
Read More
Treatment begins in phase I/II trial of SB-525 in severe hemophilia A
Read More
Yangtze River Pharmaceutical Group and collaborator patent Nav1.7 channel blockers
Read More
Fochon Pharma and collaborators present ALK inhibitors
Read More
Shenzhen Targetrx Biotechnology divulges novel CYP17A1 inhibitors
Read More
AstraZeneca initiates phase I study of AZD-5991 in relapsed or refractory hematologic malignancies
Read More
AstraZeneca AB and Eolas Therapeutics patent orexin receptor antagonists
Read More
FDA grants breakthrough therapy designation to mogamulizumab for CTCL subtypes
Read More
Roche discloses new DDR1 inhibitors
Read More
Takeda describes discovery of GPR139 agonist TAK-041 for treating negative schizophrenia symptoms
Read More
NantKwest initiates phase I study of haNK in advanced solid tumors
Read More
FDA grants priority review to Gazyva sBLA for untreated follicular lymphoma
Read More
Janssen reports findings from COMPASS trial of Xarelto in coronary and peripheral artery disease
Read More
Philogen subsidiary collaborates with Servier on small molecule discovery
Read More
Sanofi completes acquisition of Protein Sciences
Read More
Six-month results reported from phase IIb study of GNbAC-1 for relapsing-remitting MS
Read More
FDA approves Victoza to reduce risk of major adverse CV events in patients with type 2 diabetes
Read More
Xoma licenses gevokizumab commercial rights to Novartis
Read More
EMA validates for review MAAs for combination of binimetinib and encorafenib
Read More